Is There a Role for Mammalian Target of Rapamycin Inhibition in Renal Failure due to Mesangioproliferative Nephrotic Syndrome? by Hernán Trimarchi, Mariano Forrester, Fernando Lombi, Vanesa Pomeranz, Romina Iriarte, María Soledad Raña, Pablo Young

Get full text

WCN24-1884 THROMBOTIC MICROANGIOPATHY, SYSTEMIC LUPUS ERYTHEMATOSUS, AND A VITAMIN B12 MUTATION: A CAUSE OF PRIMARY ATYPICAL HEMOLYTIC UREMIC SYNDROME? by Jose Heriberto Díaz Góngora, Hernan Trimarchi, Mariano Forrester, Sandra Liliana Borda, Mariana Ursino, Matias Monkowski, Mauro Lampo

Get full text

WCN24-1921 NEPHROTIC SYNDROME SECONDARY AND FOCAL SEGMENTAL GLOMERULOSCLEROSIS DUE TO PODOCYTE KANK-2 MUTATION by Sandra Liliana Borda Galindo, Mariana Ursino, Oscar Chávez, Mauro Lampo, Matías Monkowski, Fernando Lombi, Romina Iriarte, Mariano Forrester, Hernán Trimarchi

Get full text

WCN24-1674 NEFECON TREATMENT RESPONSE IN ASIAN AND WHITE PATIENT POPULATIONS WITH IMMUNOGLOBULIN A NEPHROPATHY: A 2YEAR ANALYSIS OF THE PHASE III NEFIGARD TRIAL by Jonathan Barratt, Jens Kristensen, Andrew Stone, Jürgen Floege, Vladimír Tesař, Hernán Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Heather N. Reich, Brad H. Rovin, Richard Lafayette

Get full text

WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL by Richard Lafayette, Jens Kristensen, Andrew Stone, Jürgen Floege, Vladimír Tesař, Hernán Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Heather N. Reich, Brad H. Rovin, Jonathan Barratt

Get full text

WCN24-1777 NEFECON TREATMENT PROVIDES KIDNEY BENEFITS FOR PATIENTS WITH IgAN THAT EXTEND TO THOSE WITH LOW LEVELS OF UPCR: A SUB-ANALYSIS OF THE PHASE III NefIgArd TRIAL by Jonathan Barratt, Jens Kristensen, Andrew Stone, Jürgen Floege, Vladimír Tesař, Hernán Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Heather N. Reich, Brad H. Rovin, Richard Lafayette

Get full text

WCN24-2542 HEMODYNAMIC INESTABILITY IN DIALYSIS AS A PREDICTOR OF MORTALITY IN CRITICALLY ILL PATIENTS by Leonel Langellotti, Carolina Lozina, Briant Gauna, Eugenia Flores, Jose Diaz Gongora, Liliana Borda, Mariana Ursino, Mauro Lampo, Matias Monkowski, Romina Iriarte, Mariano Forrester, Fernando Lombi, Hernan Trimarchi

Get full text

Corrigendum to “Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy” [Volume 10, Issue 1, January 2025,... by Hiddo J.L. Heerspink, Meg Jardine, Donald E. Kohan, Richard A. Lafayette, Adeera Levin, Adrian Liew, Hong Zhang, Irene Noronha, Hernan Trimarchi, Fan Fan Hou, Ronny Renfurm, Todd Gray, Marianne Camargo, Jonathan Barratt

Get full text

Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study by Howard Trachtman, Jai Radhakrishnan, Michelle N. Rheault, Charles E. Alpers, Jonathan Barratt, Hiddo J.L. Heerspink, Irene L. Noronha, Vlado Perkovic, Brad Rovin, Hernán Trimarchi, Muh Geot Wong, Alex Mercer, Jula Inrig, William Rote, Ed Murphy, Patricia W. Bedard, Sandra Roth, Stewart Bieler, Radko Komers

Get full text